New approach for drug repurposing represents drug discovery and development which is a tedious process that requires 10-15 years of time, investments up to $1-2 billion, and have high risk of failure to enter into market for clinical applications. As the drugs has to pass through number of developmental phase, the likelihood for a drug to be approved from phase I clinical trial to United States of Food and Drug Administration (USFDA) approval is less than 10%. More than 90% of drugs failed in due to toxicity, efficacy and clinical trials. Drug repurposing is one of the roadway to accelerating drug discovery and development for treating disease and thus to providing better quality of life. This volume covers an overview of drug repurposing, novel methods, mechanism of action, lab on chip for drug repurposing, computational biology, system biology, artificial intelligence and machine learning for drug repurposing, target identification, target mining, high throughput drug screening, clinical trial of repurposed drug, repurposed biologics, and regulatory consideration and intellectual property right of repurposed drug. This volume highlights a number of aspects of the drug repurposing that can help the basic understanding of students, researchers, clinicians, entrepreneurs, and stakeholders to perform their research with great interest.
"Sinopsis" puede pertenecer a otra edición de este libro.
Prof. Vijai Singh is currently serving as Head of the Department of Biosciences, School of Science and Dean (Research & Innovation) at Indrashil University, Rajpur, Mehsana, India. Prior to this, he held the position of Associate Professor in the same department at Indrashil University. He has also served as Assistant Professor in the Department of Biological Sciences and Biotechnology at the Institute of Advanced Research, Gandhinagar, and in the Department of Biotechnology at the Invertis University, Bareilly, India. Earlier of his career, Prof. Singh worked as a Postdoctoral Fellow in the Synthetic Biology Group at the Institute of Systems and Synthetic Biology, Paris, France and at the School of Energy & Chemical Engineering at the Ulsan National Institute of Science and Technology, Ulsan, South Korea. He earned his Ph.D. in Biotechnology in 2009 from the ICAR-National Bureau of Fish Genetic Resources, Uttar Pradesh Technical University, Lucknow, India. His doctoral research focused on the development of molecular and immunoassays for the diagnosis of Aeromonas hydrophila. Prof. Singh’s research interests lies in the design and construction of novel biosynthetic pathways for production of medically and industrially important biomolecules. His laboratory is also actively engaged in developing CRISPR-Cas systems for gene knock out, knock in, gene regulation and diagnostic. With over 15 years of research and teaching experience, his areas of expertise include synthetic biology, metabolic engineering, bioinformatics, microbiology, and industrial microbiology. He has an extensive academic record, with over 110 articles, 89 book chapters, 26 books and 3 patents to his credits. Prof. Singh has received number of prestigious awards, including the Bioclues Innovation, Research and Development Award (2023) from the BIOCLUES Society, the Vice Chancellor's Best Research Award (2023) from Indrashil University, and the Agathiyar Chemical Biology Award (2023) from the Society of Chemical and Synthetic Biology. At Indrashil University, he currently serves as chairman of the Board of Study, and is a member of the Academic Council of Indrashil University. He also holds the position of the Member Secretary of the Institutional Biosafety Committee (IBSC) at the university. Dr. Singh is actively involved in national and international scientific advisory roles.
Advances in Drug Repurposing as Novel Approach for Discovery of New Therapeutic Modalities, Volume 205 in the Progress in Molecular Biology and Translational Science series, highlights new advances in the field, with this new volume presenting interesting chapters on Computational biology in epigenetics, Artificial intelligence and machine learning in epigenetics, CRISPR-dCas9 Systems for Epigenetic Editing for Therapeutic Applications, Epigenetics in heredity disease, Epigenetics in cancer development, diagnosis and therapy, Microbiota and epigenetics: health impact, Histone deacetylase (HDACs) Inhibitors: Clinical applications, Early epigenetic markers for precision medicine, Epigenetics of neurological diseases, Epigenetic Regulons in Alzheimer’s disease, and Epigenetics in epilepsy.
"Sobre este título" puede pertenecer a otra edición de este libro.
Librería: Brook Bookstore On Demand, Napoli, NA, Italia
Condición: new. Questo è un articolo print on demand. Nº de ref. del artículo: TPOEZFRLWB
Cantidad disponible: Más de 20 disponibles
Librería: Majestic Books, Hounslow, Reino Unido
Condición: New. Nº de ref. del artículo: 398438034
Cantidad disponible: 3 disponibles
Librería: Books Puddle, New York, NY, Estados Unidos de America
Condición: New. 1st edition NO-PA16APR2015-KAP. Nº de ref. del artículo: 26398987597
Cantidad disponible: 3 disponibles
Librería: Biblios, Frankfurt am main, HESSE, Alemania
Condición: New. Nº de ref. del artículo: 18398987591
Cantidad disponible: 3 disponibles
Librería: Revaluation Books, Exeter, Reino Unido
Hardcover. Condición: Brand New. 300 pages. 9.00x6.25x1.00 inches. In Stock. Nº de ref. del artículo: __0443223386
Cantidad disponible: 2 disponibles